<DOC>
	<DOCNO>NCT00024193</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Chemotherapy , give surgery , follow peripheral stem cell transplantation may effective treatment metastatic neuroblastoma . PURPOSE : Phase II trial study effectiveness chemotherapy , give surgery , follow peripheral stem cell transplantation treat patient metastatic neuroblastoma .</brief_summary>
	<brief_title>Chemotherapy Surgery Followed Peripheral Stem Cell Transplantation Treating Patients With Metastatic Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy induction chemotherapy follow surgical resection consolidation chemotherapy autologous peripheral blood stem cell transplantation patient metastatic neuroblastoma . - Determine tolerability feasibility regimen patient . - Determine medium long-term result patient treated regimen . OUTLINE : This multicenter study . Patients receive induction chemotherapy comprise cyclophosphamide IV 6 hour day 1 2 doxorubicin IV continuously vincristine IV continuously day 1-3 course 1 , 2 , 4 , 6 . Patients receive cisplatin IV 1 hour day 1-4 etoposide IV 2 hour day 1-3 induction course 3 , 5 , 7 . Patients also receive filgrastim ( G-CSF ) IV subcutaneously daily begin day 5 course 3 , 5 , 7 continue blood count recover . Treatment repeat every 21 day . At completion induction chemotherapy , patient undergo surgical resection . Patients complete remission receive high-dose consolidation chemotherapy comprise oral busulfan every 6 hour day -7 -3 melphalan IV 2 minute day -2 . Autologous peripheral blood stem cell ( PBSC ) reinfused day 0 . Patients n-myc tumor amplification undergo radiotherapy least 70 day PBSC transplantation . Patients follow every 6 month . PROJECTED ACCRUAL : Approximately 15-45 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary neuroblastoma OR Presence neuroblasts bone marrow associate elevation urinary catecholamine Metastatic disease demonstrate least 1 follow : Medullary invasion ( bone marrow involvement ) indicate bone uptake metaiodobenzyl guanidine I 123 bone lesion bone scan Distant metastases liver , pleura , lung , distant node No 1122 translocation PATIENT CHARACTERISTICS : Age : 1 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : See Disease Characteristics Other : No contraindication study drug PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>stage 4S neuroblastoma</keyword>
</DOC>